Recruiting NCT06739759
Ovarian Hyperstimulation Syndrome Prevention
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Antagonist protocol for IVF, Modified Agonist protocol for IVF with additive treatments as HCQ.
- Who it may be relevant to
- Registry conditions: Ovarian Hyper Stimulation Syndrome (OHSS). Basic parameters: 19 years — 42 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prophylaxis Against Ovarian Hyperstimulation Syndrome in PCOS Women
Overview
Ovarian hyperstimulation is a very hazardous complication of ICSI
Detailed description
Ovarian hyperstimulation could be mild , moderate , severe or marked
Interventions
- Drug Antagonist protocol for IVF
antagonist protocol with triggering by Decapeptyl - Drug Modified Agonist protocol for IVF with additive treatments as HCQ
giving additive drugs to agonist protocolas HCQ
Primary outcome measures
- prevention of OHSS [Time frame: within 3 weeks]
Eligibility criteria
Inclusion criteria
- Women with PCOS coming for ICSI
Exclusion criteria
- Women who donnot have PCOS
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Prevention
Study locations
Egypt · 2 centers
- Aljazeerah hospital — Giza
- Algazeerah — Giza
Identifiers
NCT: NCT06739759 · ovarian hyperstimulation